Fluoxetine treatment for prevention of relapse of depression in children and adolescents

A double-blind, placebo-controlled study

Graham J. Emslie, John H. Heiligenstein, Sharon L. Hoog, Karen Dineen Wagner, Robert L. Findling, James T. McCracken, Mary E. Nilsson, Jennie G. Jacobson

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Objective: To compare fluoxetine 20 to 60 mg/day with placebo for prevention of relapse of major depressive disorder in children and adolescents who had achieved Children's Depression Rating Scale, Revised scores of ≤28 during treatment with fluoxetine 20 to 60 mg. Method: In this 32-week relapse-prevention phase of a double-blind, multicenter, placebo-controlled 51-week study, 20 patients continued to receive their fixed dose of fluoxetine (F/F group), while 20 similar patients were switched to placebo (F/P group). Definition of relapse for the primary analysis was a Children's Depression Rating Scale, Revised score of >40 with a 2-week history of clinical deterioration or relapse in the opinion of the physician. Adverse events were compared between treatment groups to assess discontinuation-emergent adverse events. Results: Mean time to relapse was longer in the F/F recipients than in the F/P recipients (p = .046). Relapse occurred in an estimated 34% in the F/F cohort and 60% in the F/P cohort. Incidence of adverse events and tolerability were similar in the F/F and F/P groups, suggesting that fluoxetine is not associated with significant discontinuation events. Conclusions: Fluoxetine 20 to 60 mg/day was well tolerated and can significantly delay relapse of major depressive disorder symptoms in children and adolescents.

Original languageEnglish (US)
Pages (from-to)1397-1405
Number of pages9
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume43
Issue number11
DOIs
StatePublished - Nov 2004

Fingerprint

Fluoxetine
Secondary Prevention
Placebos
Depression
Recurrence
Major Depressive Disorder
Therapeutics
Physicians
Incidence

Keywords

  • Fluoxetine
  • Major depressive disorder
  • Relapse

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Fluoxetine treatment for prevention of relapse of depression in children and adolescents : A double-blind, placebo-controlled study. / Emslie, Graham J.; Heiligenstein, John H.; Hoog, Sharon L.; Wagner, Karen Dineen; Findling, Robert L.; McCracken, James T.; Nilsson, Mary E.; Jacobson, Jennie G.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 43, No. 11, 11.2004, p. 1397-1405.

Research output: Contribution to journalArticle

Emslie, Graham J. ; Heiligenstein, John H. ; Hoog, Sharon L. ; Wagner, Karen Dineen ; Findling, Robert L. ; McCracken, James T. ; Nilsson, Mary E. ; Jacobson, Jennie G. / Fluoxetine treatment for prevention of relapse of depression in children and adolescents : A double-blind, placebo-controlled study. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2004 ; Vol. 43, No. 11. pp. 1397-1405.
@article{0efdff0c939746c39c6072a6a0111d48,
title = "Fluoxetine treatment for prevention of relapse of depression in children and adolescents: A double-blind, placebo-controlled study",
abstract = "Objective: To compare fluoxetine 20 to 60 mg/day with placebo for prevention of relapse of major depressive disorder in children and adolescents who had achieved Children's Depression Rating Scale, Revised scores of ≤28 during treatment with fluoxetine 20 to 60 mg. Method: In this 32-week relapse-prevention phase of a double-blind, multicenter, placebo-controlled 51-week study, 20 patients continued to receive their fixed dose of fluoxetine (F/F group), while 20 similar patients were switched to placebo (F/P group). Definition of relapse for the primary analysis was a Children's Depression Rating Scale, Revised score of >40 with a 2-week history of clinical deterioration or relapse in the opinion of the physician. Adverse events were compared between treatment groups to assess discontinuation-emergent adverse events. Results: Mean time to relapse was longer in the F/F recipients than in the F/P recipients (p = .046). Relapse occurred in an estimated 34{\%} in the F/F cohort and 60{\%} in the F/P cohort. Incidence of adverse events and tolerability were similar in the F/F and F/P groups, suggesting that fluoxetine is not associated with significant discontinuation events. Conclusions: Fluoxetine 20 to 60 mg/day was well tolerated and can significantly delay relapse of major depressive disorder symptoms in children and adolescents.",
keywords = "Fluoxetine, Major depressive disorder, Relapse",
author = "Emslie, {Graham J.} and Heiligenstein, {John H.} and Hoog, {Sharon L.} and Wagner, {Karen Dineen} and Findling, {Robert L.} and McCracken, {James T.} and Nilsson, {Mary E.} and Jacobson, {Jennie G.}",
year = "2004",
month = "11",
doi = "10.1097/01.chi.0000140453.89323.57",
language = "English (US)",
volume = "43",
pages = "1397--1405",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Fluoxetine treatment for prevention of relapse of depression in children and adolescents

T2 - A double-blind, placebo-controlled study

AU - Emslie, Graham J.

AU - Heiligenstein, John H.

AU - Hoog, Sharon L.

AU - Wagner, Karen Dineen

AU - Findling, Robert L.

AU - McCracken, James T.

AU - Nilsson, Mary E.

AU - Jacobson, Jennie G.

PY - 2004/11

Y1 - 2004/11

N2 - Objective: To compare fluoxetine 20 to 60 mg/day with placebo for prevention of relapse of major depressive disorder in children and adolescents who had achieved Children's Depression Rating Scale, Revised scores of ≤28 during treatment with fluoxetine 20 to 60 mg. Method: In this 32-week relapse-prevention phase of a double-blind, multicenter, placebo-controlled 51-week study, 20 patients continued to receive their fixed dose of fluoxetine (F/F group), while 20 similar patients were switched to placebo (F/P group). Definition of relapse for the primary analysis was a Children's Depression Rating Scale, Revised score of >40 with a 2-week history of clinical deterioration or relapse in the opinion of the physician. Adverse events were compared between treatment groups to assess discontinuation-emergent adverse events. Results: Mean time to relapse was longer in the F/F recipients than in the F/P recipients (p = .046). Relapse occurred in an estimated 34% in the F/F cohort and 60% in the F/P cohort. Incidence of adverse events and tolerability were similar in the F/F and F/P groups, suggesting that fluoxetine is not associated with significant discontinuation events. Conclusions: Fluoxetine 20 to 60 mg/day was well tolerated and can significantly delay relapse of major depressive disorder symptoms in children and adolescents.

AB - Objective: To compare fluoxetine 20 to 60 mg/day with placebo for prevention of relapse of major depressive disorder in children and adolescents who had achieved Children's Depression Rating Scale, Revised scores of ≤28 during treatment with fluoxetine 20 to 60 mg. Method: In this 32-week relapse-prevention phase of a double-blind, multicenter, placebo-controlled 51-week study, 20 patients continued to receive their fixed dose of fluoxetine (F/F group), while 20 similar patients were switched to placebo (F/P group). Definition of relapse for the primary analysis was a Children's Depression Rating Scale, Revised score of >40 with a 2-week history of clinical deterioration or relapse in the opinion of the physician. Adverse events were compared between treatment groups to assess discontinuation-emergent adverse events. Results: Mean time to relapse was longer in the F/F recipients than in the F/P recipients (p = .046). Relapse occurred in an estimated 34% in the F/F cohort and 60% in the F/P cohort. Incidence of adverse events and tolerability were similar in the F/F and F/P groups, suggesting that fluoxetine is not associated with significant discontinuation events. Conclusions: Fluoxetine 20 to 60 mg/day was well tolerated and can significantly delay relapse of major depressive disorder symptoms in children and adolescents.

KW - Fluoxetine

KW - Major depressive disorder

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=6944246219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6944246219&partnerID=8YFLogxK

U2 - 10.1097/01.chi.0000140453.89323.57

DO - 10.1097/01.chi.0000140453.89323.57

M3 - Article

VL - 43

SP - 1397

EP - 1405

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 11

ER -